|
Octreotide acetate
resources
DRUG INFO
Octreotide acetate
Drug Name:
Octreotide acetate
|
|
|
Indication: For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Pharmacology: Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.
Mechanism Of Action: Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
Drug Category: Hormone replacement; Anabolic Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Sandostatin LAR; Sandostatin LAR
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Octreotide acetate
Chemical Formula: C49H66N10O10S2.2C2H4O2
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00088
CAS Registry Number: 83150-76-9
| | |
